Comment on CMS-2026-1255-0001

Summary: The Biotechnology Innovation Organization (BIO) supports the proposed rule to expand electronic prior authorization (ePA) and standardize interoperability for prescription drugs. They argue that while these technical standards are a positive first step, CMS must also implement guardrails to ensure ePA doesn't become a barrier to care, and they specifically urge the rescission of the Medicare Advantage Part B Drug Step Therapy Policy.